Recent trends in erythropoietin-mediated neuroprotection

International Journal of Developmental Neuroscience

Volumn 26, Issue 1, 2008, Pages 103-111

  McPherson, Ronald J ^a   Juul, Sandra E ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Attention deficit hyperactivity disorder; Dopamine; Neuroprotection; Prematurity; Retinopathy of prematurity

Indexed keywords

DOPAMINE; RECOMBINANT ERYTHROPOIETIN;

APOPTOSIS; ASPHYXIA; ATTENTION DEFICIT DISORDER; BLOOD BRAIN BARRIER; BRAIN INJURY; CEREBRAL PALSY; CLINICAL TRIAL; DOPAMINERGIC ACTIVITY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; HEARING IMPAIRMENT; HUMAN; MENTAL DEFICIENCY; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; PERINATAL DEVELOPMENT; PREMATURITY; PRIORITY JOURNAL; RETINOPATHY; REVIEW; VISUAL IMPAIRMENT; WHITE MATTER;

ANIMALS; BRAIN INJURIES; ERYTHROPOIETIN; HUMANS; NEUROPROTECTIVE AGENTS;

EID: 38849206183     PISSN: 07365748     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijdevneu.2007.08.012     Document Type: Review

References (135)

1. Agnello D., Bigini P., Villa P., Mennini T., Cerami A., Brines M.L., and Ghezzi P. Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis. Brain Res. 952 (2002) 128-134
2. Aher S., and Ohlsson A. Late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst. Rev. 3 (2006) (CD004868)
3. Akisu M., Tuzun S., Arslanoglu S., Yalaz M., and Kultursay N. Effect of recombinant human erythropoietin administration on lipid peroxidation and antioxidant enzyme(s) activities in preterm infants. Acta Med. Okayama 55 (2001) 357-362
4. Akkoyun I., Oto S., Yilmaz G., Gurakan B., Tarcan A., Anuk D., Akgun S., and Akova Y.A. Risk factors in the development of mild and severe retinopathy of prematurity. J. Aapos. 10 (2006) 449-453
5. Anderson P., and Doyle L.W. Neurobehavioral outcomes of school-age children born extremely low birth weight or very preterm in the 1990s. JAMA 289 (2003) 3264-3272
6. Anon., 2007. http://www.fda.gov/medwatch/safety/2005/Epogen_PI_10-26-05.pdf.Pages.
7. Ashwal S., Cole D.J., Osborne S., Osborne T.N., and Pearce W.J. A new model of neonatal stroke: reversible middle cerebral artery occlusion in the rat pup. Pediatr. Neurol. 12 (1995) 191-196
8. Back S.A., Luo N.L., Mallinson R.A., O'Malley J.P., Wallen L.D., Frei B., Morrow J.D., Petito C.K., Roberts Jr. C.T., Murdoch G.H., and Montine T.J. Selective vulnerability of preterm white matter to oxidative damage defined by F2-isoprostanes. Ann. Neurol. 58 (2005) 108-120
9. Bernaudin M., Bellail A., Marti H.H., Yvon A., Vivien D., Duchatelle I., Mackenzie E.T., and Petit E. Neurons and astrocytes express EPO mRNA: oxygen-sensing mechanisms that involve the redox-state of the brain. Glia 30 (2000) 271-278
10. Brines M. What evidence supports use of erythropoietin as a novel neurotherapeutic?. Oncology (Huntingt) 16 (2002) 79-89
11. Brines M.L., Ghezzi P., Keenan S., Agnello D., de Lanerolle N.C., Cerami C., Itri L.M., and Cerami A. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 10526-10531
12. Buemi M., Cavallaro E., Floccari F., Sturiale A., Aloisi C., Trimarchi M., Grasso G., Corica F., and Frisina N. Erythropoietin and the brain: from neurodevelopment to neuroprotection. Clin. Sci. (Lond.) 103 (2002) 275-282
13. Burke R.E., Macaya A., DeVivo D., Kenyon N., and Janec E.M. Neonatal hypoxic-ischemic or excitotoxic striatal injury results in a decreased adult number of substantia nigra neurons. Neuroscience 50 (1992) 559-569
14. Calapai G., Marciano M.C., Corica F., Allegra A., Parisi A., Frisina N., Caputi A.P., and Buemi M. Erythropoietin protects against brain ischemic injury by inhibition of nitric oxide formation. Eur. J. Pharmacol. 401 (2000) 349-356
15. Campana W.M., Misasi R., and O'Brien J.S. Identification of a neurotrophic sequence in erythropoietin. Int. J. Mol. Med. 1 (1998) 235-241
16. Carlini R.G., Reyes A.A., and Rothstein M. Recombinant human erythropoietin stimulates angiogenesis in vitro. Kidney Int. 47 (1995) 740-745
17. Casadevall N. Pure red cell aplasia and anti-erythropoietin antibodies in patients treated with epoetin. Nephrol. Dial. Transplant. 18 Suppl. 8 (2003) viii37-viii41
18. Catania M.A., Marciano M.C., Parisi A., Sturiale A., Buemi M., Grasso G., Squadrito F., Caputi A.P., and Calapai G. Erythropoietin prevents cognition impairment induced by transient brain ischemia in gerbils. Eur. J. Pharmacol. 437 (2002) 147-150
19. Celik M., Gokmen N., Erbayraktar S., Akhisaroglu M., Konakc S., Ulukus C., Genc S., Genc K., Sagiroglu E., Cerami A., and Brines M. Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 2258-2263
20. Chattopadhyay A., Choudhury T.D., Bandyopadhyay D., and Datta A.G. Protective effect of erythropoietin on the oxidative damage of erythrocyte membrane by hydroxyl radical. Biochem. Pharmacol. 59 (2000) 419-425
21. Chong Z.Z., Kang J.Q., and Maiese K. Hematopoietic factor erythropoietin fosters neuroprotection through novel signal transduction cascades. J. Cereb. Blood Flow Metab. 22 (2002) 503-514
22. Cook Jr. E.H., Stein M.A., Krasowski M.D., Cox N.J., Olkon D.M., Kieffer J.E., and Leventhal B.L. Association of attention-deficit disorder and the dopamine transporter gene. Am. J. Hum. Genet. 56 (1995) 993-998
23. Cornish K.M., Manly T., Savage R., Swanson J., Morisano D., Butler N., Grant C., Cross G., Bentley L., and Hollis C.P. Association of the dopamine transporter (DAT1) 10/10-repeat genotype with ADHD symptoms and response inhibition in a general population sample. Mol. Psychiatry 10 (2005) 686-698
24. Csak K., Szabo V., Szabo A., and Vannay A. Pathogenesis and genetic basis for retinopathy of prematurity. Front. Biosci. 11 (2006) 908-920
25. Dame C., Bartmann P., Wolber E., Fahnenstich H., Hofmann D., and Fandrey J. Erythropoietin gene expression in different areas of the developing human central nervous system. Brain Res. Dev. Brain Res. 125 (2000) 69-74
26. Demers E.J., McPherson R.J., and Juul S.E. Erythropoietin protects dopaminergic neurons and improves neurobehavioral outcomes in juvenile rats after neonatal hypoxia-ischemia. Pediatr. Res. 58 (2005) 297-301
27. DiBiasie A. Evidence-based review of retinopathy of prematurity prevention in VLBW and ELBW infants. Neonatal Netw. 25 (2006) 393-403
28. Digicaylioglu M., and Lipton S.A. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature 412 (2001) 641-647
29. Ehrenreich H., Hasselblatt M., Dembowski C., Cepek L., Lewczuk P., Stiefel M., Rustenbeck H.H., Breiter N., Jacob S., Knerlich F., Bohn M., Poser W., Ruther E., Kochen M., Gefeller O., Gleiter C., Wessel T.C., De Ryck M., Itri L., Prange H., Cerami A., Brines M., and Siren A.L. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol. Med. 8 (2002) 495-505
30. Fanaroff A.A., Hack M., and Walsh M.C. The NICHD neonatal research network: changes in practice and outcomes during the first 15 years. Semin. Perinatol. 27 (2003) 281-287
31. Genc S., Akhisaroglu M., Kuralay F., and Genc K. Erythropoietin restores glutathione peroxidase activity in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine-induced neurotoxicity in C57BL mice and stimulates murine astroglial glutathione peroxidase production in vitro. Neurosci. Lett. 321 (2002) 73-76
32. Genc S., Kuralay F., Genc K., Akhisaroglu M., Fadiloglu S., Yorukoglu K., Fadiloglu M., and Gure A. Erythropoietin exerts neuroprotection in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated C57/BL mice via increasing nitric oxide production. Neurosci. Lett. 298 (2001) 139-141
33. Gill M., Daly G., Heron S., Hawi Z., and Fitzgerald M. Confirmation of association between attention deficit hyperactivity disorder and a dopamine transporter polymorphism. Mol. Psychiatry 2 (1997) 311-313
34. Gluckman P.D., Wyatt J.S., Azzopardi D., Ballard R., Edwards A.D., Ferriero D.M., Polin R.A., Robertson C.M., Thoresen M., Whitelaw A., and Gunn A.J. Selective head cooling with mild systemic hypothermia after neonatal encephalopathy: multicentre randomised trial. Lancet 365 (2005) 663-670
35. Good W.V., Hardy R.J., Dobson V., Palmer E.A., Phelps D.L., Quintos M., and Tung B. The incidence and course of retinopathy of prematurity: findings from the early treatment for retinopathy of prematurity study. Pediatrics 116 (2005) 15-23
36. Gorio A., Gokmen N., Erbayraktar S., Yilmaz O., Madaschi L., Cichetti C., Di Giulio A.M., Vardar E., Cerami A., and Brines M. Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 9450-9455
37. Grasso G. Neuroprotective effect of recombinant human erythropoietin in experimental subarachnoid hemorrhage. J. Neurosurg. Sci. 45 (2001) 7-14
38. Grasso G., Buemi M., Alafaci C., Sfacteria A., Passalacqua M., Sturiale A., Calapai G., De Vico G., Piedimonte G., Salpietro F.M., and Tomasello F. Beneficial effects of systemic administration of recombinant human erythropoietin in rabbits subjected to subarachnoid hemorrhage. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 5627-5631
39. Hack M., Taylor H.G., Drotar D., Schluchter M., Cartar L., Andreias L., Wilson-Costello D., and Klein N. Chronic conditions, functional limitations, and special health care needs of school-aged children born with extremely low-birth-weight in the 1990s. JAMA 294 (2005) 318-325
40. Hack M., Youngstrom E.A., Cartar L., Schluchter M., Taylor H.G., Flannery D., Klein N., and Borawski E. Behavioral outcomes and evidence of psychopathology among very low birth weight infants at age 20 years. Pediatrics 114 (2004) 932-940
41. Haiden N., Klebermass K., Cardona F., Schwindt J., Berger A., Kohlhauser-Vollmuth C., Jilma B., and Pollak A. A randomized, controlled trial of the effects of adding vitamin B12 and folate to erythropoietin for the treatment of anemia of prematurity. Pediatrics 118 (2006) 180-188
42. Heeschen C., Aicher A., Lehmann R., Fichtlscherer S., Vasa M., Urbich C., Mildner-Rihm C., Martin H., Zeiher A.M., and Dimmeler S. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 102 (2003) 1340-1346
43. Hoyert D.L., Mathews T.J., Menacker F., Strobino D.M., and Guyer B. Annual summary of vital statistics: 2004. Pediatrics 117 (2006) 168-183
44. Hudome S., Palmer C., Roberts R.L., Mauger D., Housman C., and Towfighi J. The role of neutrophils in the production of hypoxic-ischemic brain injury in the neonatal rat. Pediatr. Res. 41 (1997) 607-616
45. Ismail N., and Ikizler T.A. Erythropoietin-induced hypertension. J. Med. Liban. 45 (1997) 25-30
46. Ivacko J.A., Sun R., and Silverstein F.S. Hypoxic-ischemic brain injury induces an acute microglial reaction in perinatal rats. Pediatr. Res. 39 (1996) 39-47
47. Jackson-Lewis V., Vila M., Djaldetti R., Guegan C., Liberatore G., Liu J., O'Malley K.L., Burke R.E., and Przedborski S. Developmental cell death in dopaminergic neurons of the substantia nigra of mice. J. Comp. Neurol. 424 (2000) 476-488
48. Junk A.K., Mammis A., Savitz S.I., Singh M., Roth S., Malhotra S., Rosenbaum P.S., Cerami A., Brines M., and Rosenbaum D.M. Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 10659-10664
49. Juul S.E., and Felderhoff-Mueser U. Epo and other hematopoietic factors. Semin. Fetal Neonatal Med. 12 (2007) 250-258
50. Juul S.E., Anderson D.K., Li Y., and Christensen R.D. Erythropoietin and erythropoietin receptor in the developing human central nervous system. Pediatr. Res. 43 (1998) 40-49
51. Juul S.E., Aylward E., Richards T., McPherson R.J., Kuratani J., and Burbacher T. Prenatal Cord Clamping in Newborn Macaca nemestrina: a model of perinatal asphyxia. Dev. Neurosci. 29 (2007) 311-320
52. Juul S.E., Harcum J., Li Y., and Christensen R.D. Erythropoietin is present in the cerebrospinal fluid of neonates. J. Pediatr. 130 (1997) 428-430
53. Juul S.E., McPherson R.J., Farrell F.X., Jolliffe L., Ness D.J., and Gleason C.A. Erythropoietin concentrations in cerebrospinal fluid of nonhuman primates and fetal sheep following high-dose recombinant erythropoietin. Biol. Neonate 85 (2004) 138-144
54. Juul S.E., Stallings S.A., and Christensen R.D. Erythropoietin in the cerebrospinal fluid of neonates who sustained CNS injury. Pediatr. Res. 46 (1999) 543-547
55. Juul S.E., Yachnis A.T., Rojiani A.M., and Christensen R.D. Immunohistochemical localization of erythropoietin and its receptor in the developing human brain. Pediatr. Dev. Pathol. 2 (1999) 148-158
56. Kadhim H., Tabarki B., De Prez C., and Sebire G. Cytokine immunoreactivity in cortical and subcortical neurons in periventricular leukomalacia: are cytokines implicated in neuronal dysfunction in cerebral palsy?. Acta Neuropathol. (Berl.) 105 (2003) 209-216
57. Kawakami M., Sekiguchi M., Sato K., Kozaki S., and Takahashi M. Erythropoietin receptor-mediated inhibition of exocytotic glutamate release confers neuroprotection during chemical ischemia. J. Biol. Chem. 276 (2001) 39469-39475
58. Kellert B.A., McPherson R.J., and Juul S.E. A comparison of high-dose recombinant erythropoietin treatment regimens in brain-injured neonatal rats. Pediatr. Res. 61 (2007) 451-455
59. Knabe W., Knerlich F., Washausen S., Kietzmann T., Siren A.L., Brunnett G., Kuhn H.J., and Ehrenreich H. Expression patterns of erythropoietin and its receptor in the developing midbrain. Anat. Embryol. (Berl.) 207 (2004) 503-512
60. Konishi Y., Chui D.H., Hirose H., Kunishita T., and Tabira T. Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic neurons in vitro and in vivo. Brain Res. 609 (1993) 29-35
61. Koshimura K., Murakami Y., Sohmiya M., Tanaka J., and Kato Y. Effects of erythropoietin on neuronal activity. J. Neurochem. 72 (1999) 2565-2572
62. Koury M.J., and Bondurant M.C. The molecular mechanism of erythropoietin action. Eur. J. Biochem. 210 (1992) 649-663
63. Krageloh-Mann I., Toft P., Lunding J., Andresen J., Pryds O., and Lou H.C. Brain lesions in preterms: origin, consequences and compensation. Acta Paediatr. 88 (1999) 897-908
64. Kumral A., Baskin H., Gokmen N., Yilmaz O., Genc K., Genc S., Tatli M.M., Duman N., Ozer E., and Ozkan H. Selective inhibition of nitric oxide in hypoxic-ischemic brain model in newborn rats: is it an explanation for the protective role of erythropoietin?. Biol. Neonate 85 (2004) 51-54
65. Kumral A., Gonenc S., Acikgoz O., Sonmez A., Genc K., Yilmaz O., Gokmen N., Duman N., and Ozkan H. Erythropoietin increases glutathione peroxidase enzyme activity and decreases lipid peroxidation levels in hypoxic-ischemic brain injury in neonatal rats. Biol. Neonate 87 (2005) 15-18
66. Kumral A., Uysal N., Tugyan K., Sonmez A., Yilmaz O., Gokmen N., Kiray M., Genc S., Duman N., Koroglu T.F., Ozkan H., and Genc K. Erythropoietin improves long-term spatial memory deficits and brain injury following neonatal hypoxia-ischemia in rats. Behav. Brain Res. 153 (2004) 77-86
67. Labaune J.M., Boutroy M.J., and Bairam A. Age-related modulation of dopamine d1 receptor mRNA level by hypoxia in rabbit adrenal gland. Biol. Neonate 83 (2003) 217-223
68. Laptook A.R., O'Shea T.M., Shankaran S., and Bhaskar B. Adverse neurodevelopmental outcomes among extremely low birth weight infants with a normal head ultrasound: prevalence and antecedents. Pediatrics 115 (2005) 673-680
69. Lawn J.E., Cousens S., and Zupan J. 4 million neonatal deaths: When? Where? Why?. Lancet 365 (2005) 891-900
70. Lee J.Y., Koh H.C., Chang M.Y., Park C.H., Lee Y.S., and Lee S.H. Erythropoietin and bone morphogenetic protein 7 mediate ascorbate-induced dopaminergic differentiation from embryonic mesencephalic precursors. Neuroreport 14 (2003) 1401-1404
71. Levine S., and Wenk E.J. Central nervous system hemorrhages induced by heparin in rats with allergic encephalomyelitis. Thromb. Diath. Haemorrh. 16 (1966) 296-301
72. Li Q., Lu G., Antonio G.E., Mak Y.T., Rudd J.A., Fan M., and Yew D.T. The usefulness of the spontaneously hypertensive rat to model attention-deficit/hyperactivity disorder (ADHD) may be explained by the differential expression of dopamine-related genes in the brain. Neurochem. Int. 50 (2007) 848-857
73. Li Y., Juul S.E., Morris-Wiman J.A., Calhoun D.A., and Christensen R.D. Erythropoietin receptors are expressed in the central nervous system of mid-trimester human fetuses. Pediatr. Res. 40 (1996) 376-380
74. Lin F.K., Suggs S., Lin C.H., Browne J.K., Smalling R., Egrie J.C., Chen K.K., Fox G.M., Martin F., Stabinsky Z., et al. Cloning and expression of the human erythropoietin gene. Proc. Natl. Acad. Sci. U.S.A. 82 (1985) 7580-7584
75. Lindstrom K., Lagerroos P., Gillberg C., and Fernell E. Teenage outcome after being born at term with moderate neonatal encephalopathy. Pediatr. Neurol. 35 (2006) 268-274
76. Lonchampt M., Pennel L., and Duhault J. Hyperoxia/normoxia-driven retinal angiogenesis in mice: a role for angiotensin II. Invest. Ophthalmol. Vis. Sci. 42 (2001) 429-432
77. Marshall J.F., Berrios N., and Sawyer S. Neostriatal dopamine and sensory inattention. J. Comp. Physiol. Psychol. 94 (1980) 833-846
78. Maslim J., Valter K., Egensperger R., Hollander H., and Stone J. Tissue oxygen during a critical developmental period controls the death and survival of photoreceptors. Invest. Ophthalmol. Vis. Sci. 38 (1997) 1667-1677
79. Masuda S., Okano M., Yamagishi K., Nagao M., Ueda M., and Sasaki R. A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes. J. Biol. Chem. 269 (1994) 19488-19493
80. McDonald J.W., Behrens M.I., Chung C., Bhattacharyya T., and Choi D.W. Susceptibility to apoptosis is enhanced in immature cortical neurons. Brain Res. 759 (1997) 228-232
81. McPherson R.J., Demers E.J., and Juul S.E. Safety of high-dose recombinant erythropoietin in a neonatal rat model. Neonatology 91 (2007) 36-43
82. Meadow W., Lee G., Lin K., and Lantos J. Changes in mortality for extremely low birth weight infants in the 1990s: implications for treatment decisions and resource use. Pediatrics 113 (2004) 1223-1229
83. Mehler-Wex C., Riederer P., and Gerlach M. Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson's disease, schizophrenia and attention deficit hyperactivity disorder. Neurotox. Res. 10 (2006) 167-179
84. Meng S.Z., Ohyu J., Itoh M., and Takashima S. Dopamine transporter and nitric oxide synthase in hypoxic-ischemic brain. Pediatr. Neurol. 22 (2000) 115-121
85. Morishita E., Masuda S., Nagao M., Yasuda Y., and Sasaki R. Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience 76 (1997) 105-116
86. Morita M., Ohneda O., Yamashita T., Takahashi S., Suzuki N., Nakajima O., Kawauchi S., Ema M., Shibahara S., Udono T., Tomita K., Tamai M., Sogawa K., Yamamoto M., and Fujii-Kuriyama Y. HLF/HIF-2alpha is a key factor in retinopathy of prematurity in association with erythropoietin. Embo J. 22 (2003) 1134-1146
87. Nagai A., Nakagawa E., Choi H.B., Hatori K., Kobayashi S., and Kim S.U. Erythropoietin and erythropoietin receptors in human CNS neurons, astrocytes, microglia, and oligodendrocytes grown in culture. J. Neuropathol. Exp. Neurol. 60 (2001) 386-392
88. Nieoullon A. Dopamine and the regulation of cognition and attention. Prog. Neurobiol. 67 (2002) 53-83
89. Northington F.J., Ferriero D.M., Flock D.L., and Martin L.J. Delayed neurodegeneration in neonatal rat thalamus after hypoxia-ischemia is apoptosis. J. Neurosci. 21 (2001) 1931-1938
90. Northington F.J., Ferriero D.M., Graham E.M., Traystman R.J., and Martin L.J. Early neurodegeneration after hypoxia-ischemia in neonatal rat is necrosis while delayed neuronal death is apoptosis. Neurobiol. Dis. 8 (2001) 207-219
91. Ohlsson A., and Aher S.M. Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst. Rev. 3 (2006) (CD004863)
92. Oppenheim R.W. Cell death during development of the nervous system. Annu. Rev. Neurosci. 14 (1991) 453-501
93. Palmer C., Menzies S.L., Roberts R.L., Pavlick G., and Connor J.R. Changes in iron histochemistry after hypoxic-ischemic brain injury in the neonatal rat. J. Neurosci. Res. 56 (1999) 60-71
94. Palmer E.A., Flynn J.T., Hardy R.J., Phelps D.L., Phillips C.L., Schaffer D.B., and Tung B. Incidence and early course of retinopathy of prematurity. The Cryotherapy for Retinopathy of Prematurity Cooperative Group. Ophthalmology 98 (1991) 1628-1640
95. Pang Y., Cai Z., and Rhodes P.G. Effects of lipopolysaccharide on oligodendrocyte progenitor cells are mediated by astrocytes and microglia. J. Neurosci. Res. 62 (2000) 510-520
96. Patra K., Wilson-Costello D., Taylor H.G., Mercuri-Minich N., and Hack M. Grades I-II intraventricular hemorrhage in extremely low birth weight infants: effects on neurodevelopment. J. Pediatr. 149 (2006) 169-173
97. Perlman J.M. Summary proceedings from the neurology group on hypoxic-ischemic encephalopathy. Pediatrics 117 (2006) S28-S33
98. Quiram P.A., and Capone Jr. A. Current understanding and management of retinopathy of prematurity. Curr. Opin. Ophthalmol. 18 (2007) 228-234
99. Renzi M.J., Farrell F.X., Bittner A., Galindo J.E., Morton M., Trinh H., and Jolliffe L.K. Erythropoietin induces changes in gene expression in PC-12 cells. Brain Res. Mol. Brain Res. 104 (2002) 86-95
100. Ribatti D., Presta M., Vacca A., Ria R., Giuliani R., Dell'Era P., Nico B., Roncali L., and Dammacco F. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 93 (1999) 2627-2636
101. Rice III J.E., Vannucci R.C., and Brierley J.B. The influence of immaturity on hypoxic-ischemic brain damage in the rat. Ann. Neurol. 9 (1981) 131-141
102. Roberto K.A., Tolman B.L., and Penn J.S. Long-term retinal vascular abnormalities in an animal model of retinopathy of prematurity. Curr. Eye Res. 15 (1996) 932-937
103. Russell V., de Villiers A., Sagvolden T., Lamm M., and Taljaard J. Altered dopaminergic function in the prefrontal cortex, nucleus accumbens and caudate-putamen of an animal model of attention-deficit hyperactivity disorder-the spontaneously hypertensive rat. Brain Res. 676 (1995) 343-351
104. Russell V.A. Dopamine hypofunction possibly results from a defect in glutamate-stimulated release of dopamine in the nucleus accumbens shell of a rat model for attention deficit hyperactivity disorder-the spontaneously hypertensive rat. Neurosci. Biobehav. Rev. 27 (2003) 671-682
105. Russell V.A. Neurobiology of animal models of attention-deficit hyperactivity disorder. J. Neurosci. Meth. 161 (2007) 185-198
106. Sakanaka M., Wen T.C., Matsuda S., Masuda S., Morishita E., Nagao M., and Sasaki R. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 4635-4640
107. Sandercoe T.M., Geller S.F., Hendrickson A.E., Stone J., and Provis J.M. VEGF expression by ganglion cells in central retina before formation of the foveal depression in monkey retina: evidence of developmental hypoxia. J. Comp. Neurol. 462 (2003) 42-54
108. Shankaran S., Laptook A.R., Ehrenkranz R.A., Tyson J.E., McDonald S.A., Donovan E.F., Fanaroff A.A., Poole W.K., Wright L.L., Higgins R.D., Finer N.N., Carlo W.A., Duara S., Oh W., Cotten C.M., Stevenson D.K., Stoll B.J., Lemons J.A., Guillet R., and Jobe A.H. Whole-body hypothermia for neonates with hypoxic-ischemic encephalopathy. N. Engl. J. Med. 353 (2005) 1574-1584
109. Silva M., Benito A., Sanz C., Prosper F., Ekhterae D., Nunez G., and Fernandez-Luna J.L. Erythropoietin can induce the expression of bcl-x(L) through Stat5 in erythropoietin-dependent progenitor cell lines. J. Biol. Chem. 274 (1999) 22165-22169
110. Siren A.L., Fratelli M., Brines M., Goemans C., Casagrande S., Lewczuk P., Keenan S., Gleiter C., Pasquali C., Capobianco A., Mennini T., Heumann R., Cerami A., Ehrenreich H., and Ghezzi P. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 4044-4049
111. Smith L.E., Wesolowski E., McLellan A., Kostyk S.K., D'Amato R., Sullivan R., and D'Amore P.A. Oxygen-induced retinopathy in the mouse. Invest. Ophthalmol. Vis. Sci. 35 (1994) 101-111
112. Sobh M.A., el-Tantawy A.E., Said E., Atta M.G., Refaie A., Nagati M., and Ghoneim M. Effect of treatment of anaemia with erythropoietin on neuromuscular function in patients on long term haemodialysis. Scand. J. Urol. Nephrol. 26 (1992) 65-69
113. Springborg J.B., Ma X., Rochat P., Knudsen G.M., Amtorp O., Paulson O.B., Juhler M., and Olsen N.V. A single subcutaneous bolus of erythropoietin normalizes cerebral blood flow autoregulation after subarachnoid haemorrhage in rats. Br. J. Pharmacol. 135 (2002) 823-829
114. Statler P.A., McPherson R.J., Bauer L.A., Kellert B.A., and Juul S.E. Pharmacokinetics of high-dose recombinant erythropoietin in plasma and brain of neonatal rats. Pediatr. Res. 61 (2007) 1-5
115. Studer L., Csete M., Lee S.H., Kabbani N., Walikonis J., Wold B., and McKay R. Enhanced proliferation, survival, and dopaminergic differentiation of CNS precursors in lowered oxygen. J. Neurosci. 20 (2000) 7377-7383
116. Sugawa M., Sakurai Y., Ishikawa-Ieda Y., Suzuki H., and Asou H. Effects of erythropoietin on glial cell development; oligodendrocyte maturation and astrocyte proliferation. Neurosci. Res. 44 (2002) 391-403
117. Sullivan R.M., and Brake W.G. What the rodent prefrontal cortex can teach us about attention-deficit/hyperactivity disorder: the critical role of early developmental events on prefrontal function. Behav. Brain Res. 146 (2003) 43-55
118. Sun Y., Calvert J.W., and Zhang J.H. Neonatal hypoxia/ischemia is associated with decreased inflammatory mediators after erythropoietin administration. Stroke 36 (2005) 1672-1678
119. Steinkuller P.G., Du L., Gilbert C., Foster A., Collins M.L., and Coats D.K. Childhood blindness. J. Aapos. 3 (1999) 26-32
120. Vairano M., Dello Russo C., Pozzoli G., Battaglia A., Scambia G., Tringali G., Aloe-Spiriti M.A., Preziosi P., and Navarra P. Erythropoietin exerts anti-apoptotic effects on rat microglial cells in vitro. Eur. J. Neurosci. 16 (2002) 584-592
121. Vannucci R.C. Experimental biology of cerebral hypoxia-ischemia: relation to perinatal brain damage. Pediatr. Res. 27 (1990) 317-326
122. Vannucci R.C. Hypoxia-ischemia: clinical aspects. Neonatal-Perinatal Medicine IV (1997), Mosby-Yearbook Inc., Philadelphia pp. 877-891
123. Vannucci R.C., and Perlman J.M. Interventions for perinatal hypoxic-ischemic encephalopathy. Pediatrics 100 (1997) 1004-1014
124. Villa P., Bigini P., Mennini T., Agnello D., Laragione T., Cagnotto A., Viviani B., Marinovich M., Cerami A., Coleman T.R., Brines M., and Ghezzi P. Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J. Exp. Med. 198 (2003) 971-975
125. Vohr B.R., Wright L.L., Dusick A.M., Perritt R., Poole W.K., Tyson J.E., Steichen J.J., Bauer C.R., Wilson-Costello D.E., and Mayes L.C. Center differences and outcomes of extremely low birth weight infants. Pediatrics 113 (2004) 781-789
126. Volpe J.J. Perinatal brain injury: from pathogenesis to neuroprotection. Ment. Retard. Dev. Disabil. Res. Rev. 7 (2001) 56-64
127. Watanabe D., Suzuma K., Matsui S., Kurimoto M., Kiryu J., Kita M., Suzuma I., Ohashi H., Ojima T., Murakami T., Kobayashi T., Masuda S., Nagao M., Yoshimura N., and Takagi H. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N. Engl. J. Med. 353 (2005) 782-792
128. Watts D.H., Krohn M.A., Hillier S.L., and Eschenbach D.A. The association of occult amniotic fluid infection with gestational age and neonatal outcome among women in preterm labor. Obstet. Gynecol. 79 (1992) 351-357
129. Whitelaw A., and Thoresen M. Clinical trials of treatments after perinatal asphyxia. Curr. Opin. Pediatr. 14 (2002) 664-668
130. Wilson-Costello D., Friedman H., Minich N., Fanaroff A.A., and Hack M. Improved survival rates with increased neurodevelopmental disability for extremely low birth weight infants in the 1990s. Pediatrics 115 (2005) 997-1003
131. Wolf R.F., Gilmore L.S., Friese P., Downs T., Burstein S.A., and Dale G.L. Erythropoietin potentiates thrombus development in a canine arterio-venous shunt model. Thromb. Haemost. 77 (1997) 1020-1024
132. Yamamoto M., Koshimura K., Kawaguchi M., Sohmiya M., Murakami Y., and Kato Y. Stimulating effect of erythropoietin on the release of dopamine and acetylcholine from the rat brain slice. Neurosci. Lett. 292 (2000) 131-133
133. Zhang W., Ghetti B., and Lee W.H. Decreased IGF-I gene expression during the apoptosis of Purkinje cells in pcd mice. Brain Res. Dev. Brain Res. 98 (1997) 164-176
134. Zhang W., Ito Y., Berlin E., Roberts R., and Berkowitz B.A. Role of hypoxia during normal retinal vessel development and in experimental retinopathy of prematurity. Invest. Ophthalmol. Vis. Sci. 44 (2003) 3119-3123
135. Zhang Y., and Stone J. Role of astrocytes in the control of developing retinal vessels. Invest. Ophthalmol. Vis. Sci. 38 (1997) 1653-1666